194 related articles for article (PubMed ID: 9349684)
1. Properties of intraepithelial neoplasia relevant to cancer chemoprevention and to the development of surrogate end points for clinical trials.
Boone CW; Bacus JW; Bacus JV; Steele VE; Kelloff GJ
Proc Soc Exp Biol Med; 1997 Nov; 216(2):151-65. PubMed ID: 9349684
[TBL] [Abstract][Full Text] [Related]
2. Properties of intraepithelial neoplasia relevant to the development of cancer chemopreventive agents.
Boone CW; Bacus JW; Bacus JV; Steele VE; Kelloff GJ
J Cell Biochem Suppl; 1997; 28-29():1-20. PubMed ID: 9589346
[TBL] [Abstract][Full Text] [Related]
3. Development of surrogate endpoint biomarkers for clinical trials of cancer chemopreventive agents: relationships to fundamental properties of preinvasive (intraepithelial) neoplasia.
Boone CW; Kelloff GJ
J Cell Biochem Suppl; 1994; 19():10-22. PubMed ID: 7823580
[TBL] [Abstract][Full Text] [Related]
4. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
5. Intraepithelial and postinvasive neoplasia as a stochastic continuum of clonal evolution, and its relationship to mechanisms of chemopreventive drug action.
Boone CW; Kelloff GJ; Freedman LS
J Cell Biochem Suppl; 1993; 17G():14-25. PubMed ID: 8007692
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention trials and surrogate end point biomarkers in the cervix.
Mitchell MF; Hittelman WK; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Wharton JT; Hong WK
Cancer; 1995 Nov; 76(10 Suppl):1956-77. PubMed ID: 8634987
[TBL] [Abstract][Full Text] [Related]
7. Biomarker end-points in cancer chemoprevention trials.
Boone CW; Kelloff GJ
IARC Sci Publ; 1997; (142):273-80. PubMed ID: 9354926
[TBL] [Abstract][Full Text] [Related]
8. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
[TBL] [Abstract][Full Text] [Related]
9. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
10. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
[TBL] [Abstract][Full Text] [Related]
11. Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention.
Boone CW; Kelloff GJ
J Cell Biochem Suppl; 1993; 17F():37-48. PubMed ID: 8412208
[TBL] [Abstract][Full Text] [Related]
12. Surrogate end-point biomarkers in chemopreventive drug development.
Kelloff GJ; Sigman CC; Hawk ET; Johnson KM; Crowell JA; Guyton KZ
IARC Sci Publ; 2001; 154():13-26. PubMed ID: 11220652
[TBL] [Abstract][Full Text] [Related]
13. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
14. Endpoint markers for clinical trials of chemopreventive agents derived from the properties of epithelial precancer (intraepithelial neoplasia) measured by computer-assisted image analysis.
Boone CW; Kelloff GJ
Cancer Surv; 1998; 32():133-47. PubMed ID: 10489626
[TBL] [Abstract][Full Text] [Related]
15. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
[TBL] [Abstract][Full Text] [Related]
16. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy.
Boone CW; Kelloff GJ; Steele VE
Cancer Res; 1992 Apr; 52(7):1651-9. PubMed ID: 1551096
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
Lieberman R
Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
[TBL] [Abstract][Full Text] [Related]
18. The biology of incipient, pre-invasive or intraepithelial neoplasia.
Grizzle WE; Srivastava S; Manne U
Cancer Biomark; 2010; 9(1-6):21-39. PubMed ID: 22112468
[TBL] [Abstract][Full Text] [Related]
19. Role of the pathologist in biomarker studies.
Wilkinson EJ; Hendricks JB
J Cell Biochem Suppl; 1995; 23():10-8. PubMed ID: 8747373
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention of cancer.
Tsao AS; Kim ES; Hong WK
CA Cancer J Clin; 2004; 54(3):150-80. PubMed ID: 15195789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
